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Objective: To evaluate adherence to guidelines when choosing an empirical treatment
and its impact upon the prognosis of community-acquired pneumonia (CAP).
Methods: A prospective multicentre study was conducted in 425 CAP patients hospitalized
on ward. Initial empirical treatment was classiﬁed as adhering or not to Spanish guidelines.
Adherent treatment was deﬁned as an initial antimicrobial regimen consisting of beta-
lactams plus macrolides, beta-lactam monotherapy and quinolones. Non-adherent
treatments included macrolide monotherapy and other regimens. Initial severity was
graded according to pneumonia severity index (PSI). The end point variables were
mortality, length of stay (LOS) and re-admission at 30 days.
Results: Overall 30-day mortality was 8.2%, the mean LOS was 875 days, and the global
re-admission rate was 7.6%. Adherence to guidelines was 76.5%, and in most cases the
empirical treatment consisted of beta-lactam and macrolide in combination (57.4%).
Logistic regression analysis showed that other regimens were associated with higher
mortality OR ¼ 3 (1.2–7.3), after adjusting for PSI and admitting hospital. Beta-lactam
monotherapy was an independent risk factor for re-admission. LOS was independently
associated with admitting hospital and not with antibiotics.Elsevier Ltd. All rights reserved.
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S. Reyes Calzada et al.1910Conclusions: A high adherence to CAP treatment guidelines was found, though with
considerable variability in the empirical antibiotic treatment among hospitals. Non-
adherent other regimens were associated with greater mortality. Beta-lactam mono-
therapy was associated with an increased re-admission rate.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Community-acquired pneumonia (CAP) is one of the diseases
with the greatest morbidity–mortality in the world, and
leads to important consumption of health care resources.
The gross mortality rate due to pneumonia is 17.2 per
100,000 inhabitants in Spain,1 versus 20.9 in the United
States.2 These ﬁgures have not decreased in recent
decades.2,3 Mortality due to pneumonia can be related to
factors depending on the infection, the causal microorgan-
ism, the initial severity of the disease, and parameters
associated with medical care. The initial severity of CAP can
be quantiﬁed, but is not amenable to modiﬁcation. The
causal microorganism is, in turn, dependent upon the
geographical setting, patient co-morbidity, toxic habits,
and age among others. However, medical intervention is a
factor related to the patient prognosis that can be modiﬁed
and improved. In this context, inadequate initial antibiotic
treatment is known to be associated with important
mortality.4,5
Prescription of antibiotics in CAP is usually an empirical
selection because the causal microorganisms are unknown at
diagnosis. Furthermore, neither symptoms nor analytical
data or radiological ﬁndings allow an accurate etiologic
diagnosis. In fact, a limitation on CAP therapy studies is that
there are very few well-designed CAP treatment studies and
most of them are retrospective and non-experimental.
Guidelines to aid in the decision for empirical treatment
and patient management have been developed by scientiﬁc
societies.6–9 These guidelines stratify patients by age,
co-morbidity, risk factors for microbial resistance and/or
speciﬁc parameters for selecting the antibiotic regimen.
The choice of treatment regimen also has prognostic
implications, since different therapeutic protocols exist and
not all of them offer the same beneﬁcial effects for the
patient.10–12 Thus, treatment adherence to the guidelines,
and the use of certain antibiotic regimens such as macro-
lides plus beta-lactams and ﬂuoroquinolones have been
associated with improved outcomes.13–17 However, the
controversy remains about the beneﬁcial impact on prog-
nosis of empirical treatments with or without atypical
coverage.18,19 Two recently published meta-analyses have
shown no beneﬁcial effect when atypical coverage against
microorganisms is prescribed.20,21
Our working hypothesis is that mortality, the length of
hospital stay, and the course of CAP in hospitalized patients
depends on hospital type and the prescription of adequate
initial empirical treatment following guidelines. We there-
fore investigated adherence to the established Spanish
guidelines when choosing an empirical antibiotic treatment,
and its impact upon the prognosis of patients admitted
with CAP.Patients and methods
A prospective, observational study with a duration of one
year was carried out in four public hospitals of the
Autonomous Community of Valencia (Spain): a tertiary
hospital (Hospital A) attending 400,000 inhabitants, and
three district hospitals (B, C and D), respectively, attending
128,000, 125,000 and 54,000 inhabitants. In the tertiary
hospital there is a pneumologist on duty, while in the other
three hospitals there is an internist physician on duty; a
radiologist on duty is found in the four centres.
The study cohort included consecutive patients admitted
with CAP. The inclusion criteria were: age 418 years,
symptoms of acute respiratory infection, and the presence
of a new inﬁltrate on chest X-radiogram, with no alternative
diagnosis up until resolution. Immunocompromised patients
were excluded (human immunodeﬁciency virus infection
(HIV), transplantations, and patients receiving immunosup-
pressing drug and/or corticosteroids at doses420mg/day),
as were those with lung abscesses, tuberculosis, suspected
aspiration, admission to hospital in the previous 15 days, and
patients with pneumonia admitted to Intensive Care Unit
(ICU). Informed consent was not required by our local ethics
committee because no patient interventions were involved.
A protocol for data collection in the ﬁrst 24 h was applied
in all cases: age, sex, smoking and alcohol consumption,
vaccination status, residence for the elderly, co-morbidity
(pulmonary, heart, liver, neurological, renal, neoplasms and
diabetes mellitus). The following clinical data were re-
corded: cough, expectoration, chest pain, dyspnea, mental
alterations, temperature, heart rate, respiratory rate, and
blood pressure. Recorded analytical data were leucocyte
count, sodium, potassium, serum creatinine, glucose,
GOT/GTP, and arterial blood gas analysis. Radiological
parameters were also documented (radiological pattern,
number of affected lung lobes, pleural effusion or cavita-
tion). All patients were classiﬁed according to the pneumo-
nia severity index (PSI).22
Empiric antibiotic treatment was that one prescribed
within the ﬁrst 24 h. It was classiﬁed according to adherence
or not to the Spanish guidelines, Sociedad Espan˜ola de
Neumologı´a y Cirugı´a Tora´cica (SEPAR)6,7 and to the speciﬁc
antimicrobial regimen used. Adherence to guidelines for
patients hospitalized on ward include the following regi-
mens: beta-lactam (cefotaxime, ceftriaxone or amoxicillin-
clavulanate) plus macrolide (clarithromycin, azithromycin,
erythromycin), beta-lactam (cefotaxime, ceftriaxone or
amoxicillin-clavulanate) in monotherapy, and quinolones
(third or fourth generation). Any other antibiotic or
combination of antibiotics was considered non-adherent to
guidelines. The attending physician prescribed the initial
empiric antibiotic therapy. No interventions on prescribing
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Table 1 Demographic characteristics, co-morbidity and
PSI of the study cohort.
Patients n (%) 425 100
Age (yr) 69716
Sex (M/F) 274/151 65/35
Co-morbidity n (%)
Congestive heart failure 119 28
COPD 143 34
Diabetes mellitus 85 20
Cerebrovascular disease 63 15
Kidney disease 23 5
Liver disease 23 5
Neoplasm 35 8
Smoking 77 18
Residence for the elderly 18 4
PSI n (%)
I 31 7
II 52 12
III 93 22
IV 170 40
V 79 19
Adherence to SEPAR n (%) 325 76
LOS 875
Deaths n (%) 35 8
Re-admission n (%) 32 8
Data are presented as mean7SD; M: male; F: female;
COPD: chronic obstructive pulmonary disease; PSI: pneumo-
nia severity index; LOS: length of stay; SEPAR: Sociedad
Espan˜ola de Neumologı´a y Cirugı´a tora´cica.
Treatment of pneumonia. Impact on outcome 1911physicians were carried out prior or during the study about
SEPAR guidelines awareness.
The length of stay (LOS) in hospital was deﬁned as
the number of days of patient admission since arrival to
hospital until discharge. Follow-up was carried out 30 days
after discharge to assess the course of the patient, with
evaluation of the need for re-admission, and global mor-
tality at 30 days.
Actual and predicted 30-day mortality were compared
for each antibiotic treatment regimen. Actual mortality
was calculated dividing the number of deaths by the
number of patients given a speciﬁc antibiotic treatment.
Predicted mortality for the same groups, weighted by
severity, was calculated adding the predicted mortality for
each patient in the group and dividing by the number of
patients in that group. Predicted mortality for each patient
was the one assigned to the PSI group in which the patient
was classiﬁed (I ¼ 0.1%, II ¼ 0.6%, III ¼ 2.8%, IV ¼ 8.2%,
V ¼ 29.2%).22
Statistical analysis
A descriptive and comparative analysis was performed:
univariate analysis was based on the chi-square test for
qualitative variables, while the Student’s t-test was used for
quantitative variables. Non-parametric tests were used in
the absence of a normal distribution. Values of po0.05 were
considered statistically signiﬁcant.
Three multivariate stepwise logistic regression analyses
were carried out. Dependent variables were mortality in the
ﬁrst analysis, re-admission in the second, and prolonged LOS
(48 days) in the third. The LOS was dichotomized by the
median, and prolonged LOS was considered when LOS was
48 days (yes/no). Independent variables in the three
analyses were PSI, admitting hospital (A, B, C, D), adherence
to guidelines (yes/no) and empiric antibiotic. PSI was
dichotomized as high (Fine risk classes IV and V) or low
severity (classes I–III). Empiric antibiotic regimens were
classiﬁed as beta-lactam monotherapy, beta-lactam plus
macrolides, quinolones, macrolides monotherapy and
others. Odds ratio (OR) and 95% conﬁdence interval (CI)
were calculated, and the goodness-of-ﬁt of the models were
assessed with the Hosmer–Lemeshow test.
Results
Cohort description
A total of 425 patients were included: 229 (53.9%) admitted
to the tertiary centre, and 196 (46.1%) in the general
hospitals. The demographic and clinical characteristics are
shown in Table 1. There were no signiﬁcant differences
among the four hospitals in terms of co-morbidity, age and
sex. However, smoking habit was more frequent in hospitals
C and D, p ¼ 0.02.
Antibiotic regimens
The therapeutic adherent regimens used were: beta-lactam
plus macrolide (n ¼ 244, 57.4%), beta-lactam monotherapy(n ¼ 72, 16.9%), and quinolones (n ¼ 11, 2.6%). The non-
adherent treatments were classiﬁed as macrolide mono-
therapy (n ¼ 32; 7.5%) and others (n ¼ 66; 15.5%). The
latter included second generation cephalosporins plus
macrolides (n ¼ 33, 7.7%), ciproﬂoxacin monotherapy
(n ¼ 3, 0.7%), ciproﬂoxacin plus macrolide (n ¼ 13, 3.2%)
or plus amoxicillin-clavulanate (n ¼ 1, 0.2%), third or fourth
generation cephalosporins plus amikacin (n ¼ 5, 1.1%),
imipenem (n ¼ 4, 0.9%), second generation cephalosporins
as monotherapy (n ¼ 3, 0.7%), vancomycin plus macrolide or
antipseudomonal cephalosporin (n ¼ 3, 0.7%), piperacillin-
tazobactam (n ¼ 1, 0.2%). The distribution by groups in
each hospital is reported in Table 2. The most often
used treatment regimen in the four hospitals was the
combination of beta-lactams and macrolides. However,
this regimen was less frequent in hospital B (38.5%), where
an increase was seen in the use of other regimens (31.5%),
due to a higher prescription of second-generation cephalos-
porins plus macrolides. Treatment adherence to the
SEPAR guidelines for the global patient cohort was 76.5%.
Adherence differed among the hospitals, however, and
was seen to be lower in hospitals B (53.4%) and C (67.2%)
compared with hospitals A (83.8%) and D (84.6%),
p ¼ 0.0001. The distribution of the antibiotic regimens
according to PSI (Table 3) was similar in the low and
high-risk groups, except for macrolide monotherapy, which
was more frequent among the low-risk patients (13.6%
versus 3.2%).
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Table 2 Description of empiric treatment according to age, co-morbidity, length of stay, mortality and readmission.
Adherence to guidelines Non-adherence to guidelines p
Beta-lactam
+macrolide
Beta-lactam
monotherapy
Quinolone Macrolide
monotherapy
Other
regimens
Age (yr) (mean7SD) 70716 73714 72718 55721 70716 0.008
Co-morbidity n (%)
Congestive heart failure 70 (28.7) 23 (31.9) 3 (27.3) 5 (15.6) 18 (27.3) NS
COPD 80 (32.8) 25 (34.7) 5 (45.5) 10 (31.3) 23 (34.8) NS
Diabetes mellitus 50 (20.6) 16 (22.2) 0 1 (3.1) 18 (27.3) NS
Cerebrovascular disease 37 (15.2) 10 (13.9) 3 (27.3) 3 (9.7) 10 (15.4) NS
Kidney disease 16 (6.6) 5 (6.9) 0 0 2 (3.0) NS
Liver disease 15 (6.1) 3 (4.7) 1 (9.1) 2 (6.3) 2 (3.0) NS
Neoplasm 18 (7.4) 8 (11.1) 2 (18.2) 0 7 (10.6) NS
Smoking 45 (18.6) 6 (8.5) 2 (18.2) 15 (46.9) 9 (14.1) NS
Nursing home 10 (4.1) 1 (1.4) 1 (9.1) 0 6 (9.1) NS
LOS days (mean7SD) 975 1177 975 873 974 NS
Mortality n (%) 21 (8.6) 5 (6.9) 0 0 9 (13.6) NS
Re-admission n (%) 15 (6.2) 10 (13.9) 0 3 (9.4) 4 (6.1) NS
Hospital n (%)a
A 138 (60.3)b 48 (21.0)b 8 (3.5) 9 (3.9)b 26 (11.4)b
B 28 (38.4) 11 (15.1) 0 11 (15.1) 23 (31.5)
C 30 (51.7) 9 (15.5) 0 8 (13.8) 11 (19.0)
D 48 (73.8) 4 (6.2) 3 (4.6) 4 (6.2) 6 (9.2)
Total n (%) 244 (57.4) 72 (16.9) 11 (2.6) 32 (7.5) 66 (15.5)
COPD: chronic obstructive pulmonary disease; LOS: length of stay.
aComparison among hospitals of each antibiotic regimen.
bpo0.05.
Table 3 Description and comparison of initial empirical
treatment according to low or high risk class.
Antibiotic regimen PSI I–III PSI IV–V p-Value
n (%) n (%)
Beta-lactam+macrolide 91 (52) 153 (61) 0.04
n ¼ 244 (57%)
Beta-lactam monotherapy 28 (16) 44 (18) 0.6
n ¼ 72 (17%)
Quinolone 4 (2) 7 (3) 0.7
n ¼ 11 (3%)
Macrolide monotherapy 24 (14) 8 (3) 0.0001
n ¼ 32 (7%)
Other regimens 29 (16) 37 (15) 0.6
n ¼ 66 (16%)
Total 176 (100) 249 (100)
PSI I–III: Pneumonia severity index (classes I–III).
PSI IV–V: Pneumonia severity index (classes IV–V).
S. Reyes Calzada et al.1912Mortality
Overall mortality was 8.2%, with no signiﬁcant differences
among hospitals. Mortality in adherent group was 26 (8.2%)and in non-adherent group was 9 (8.5%) p ¼ 0.9, and no
differences were found after stratifying for PSI either. The
global mortality for each antibiotic regimen and according
to PSI is shown in Table 4. No signiﬁcant differences in global
mortality were seen among the different treatment regi-
mens. In the low-risk group, higher mortality was found
among the patients treated with beta-lactam monotherapy
(7.1%), although it was not statistically signiﬁcant. In the
high-risk group (Fine classes IV–V), mortality was higher in
the group administered other regimens (24.3%), p ¼ 0.02.
A detailed 30-day mortality analysis was made for each
antibiotic regimen (Fig. 1). This ﬁgure compares actual and
predicted mortality rates. Actual mortality for all antibiotic
regimens was seen to be lower than the predicted value,
except for the other regimens group. In this latter group,
actual mortality was greater than predicted from PSI, with a
30.2% increase in deaths.Length of stay
The median LOS was 8 days. The median LOS in adherent
group and in non-adherent group was 8 days, p ¼ 0.6.
On analysing LOS by hospitals, shorter stays were recorded
in hospital D, with a median of 6 days, p ¼ 0.0001.
There were no statistically signiﬁcant differences in LOS
with respect to the different antibiotic regimens and PSI,
p ¼ 0.4 (Table 4).
ARTICLE IN PRESS
0
0
9.5
13.2
11.71
8.8
10.2
13.6
6.9
8.6
0 4 8 10 122 14 16
Other regimens
Macrolide monotherapy
Quinolone
Beta-lactam monotherapy
Beta-lactam+macrolide
A
nt
ib
io
tic
 re
gi
m
en
Mortality(%)
Predicted mortality Actual mortality
6
Figure 1 Actual and predicted 30-day mortality for each antibiotic regimen.
Table 4 Mortality, length of hospital stay and re-admission according to antibiotic treatment and PSI.
Antibiotic regimen Mortality n (%) LOS (median)a Re-admission n (%)b
PSI: I–III PSI: IV–V PSI: I–III PSI: IV–V PSI: I–III PSI: IV–V
Beta-lactam+ macrolide 1 (1.1) 20 (13.1) 8 8 4 (1.7) 11 (4.5)
Beta-lactam monotherapy 2 (7.1) 3 (6.8) 8 9 4 (5.6) 6 (8.3)
Quinolone 0 0 8 8 0 0
Macrolide monotherapy 0 0 8 8 1 (3.1) 2 (6.3)
Other regimens 0 9 (24.3)c 8 8 0 4 (6.1)
Total 3 (1.7) 32 (12.9) 8 8 9 (2.1) 23 (5.4)
PSI: Pneumonia severity index; LOS: length of stay.
ap ¼ 0.4: comparison median LOS in low-risk patients versus high-risk group.
bp ¼ 0.07: comparison re-admission in low-risk patients 2.1% versus 5.4% in the high-risk group.
cp ¼ 0.02: in the high-risk group, mortality was greater in the group administered other regimens (24.3%).
Treatment of pneumonia. Impact on outcome 1913Re-admission
Thirty-two patients were readmitted within 30 days after
hospital discharge (7.6%). The re-admission in adherent
group was 7 (6.6%) and in non-adherent group was 25 (7.9%),
p ¼ 0.6. The distribution by hospitals was: 17 patients in
hospital A (7.5%), 6 in hospital B (8.3%), 6 in hospital C
(10.3%), and 3 patients in hospital D (4.6%), p ¼ 0.6. No
signiﬁcant differences were found in re-admission with
respect to the initial treatment regimen used. However,
re-admission was related to initial severity (2.1% re-
admission in low-risk patients versus 5.4% in the high-risk
group), though not to a statistically signiﬁcant difference
(p ¼ 0.07) (Table 4).Multivariate analysis
Three logistic regression analyses were made to predict
mortality, re-admission and prolonged LOS. The independent
risk factors for mortality were PSI (OR ¼ 11.1, 95% CI
2.6–48.1), and treatment with other regimens (OR ¼ 3,
1.2–7.3). Beta-lactam monotherapy was found to be an
independent risk factor for re-admission (OR ¼ 2.7, 1.2–6.1),
and in the third model, admission to hospital D was found to
be protective for prolonged LOS (OR ¼ 0.2, 0.1–0.5).Discussion
The most relevant ﬁndings of the present study are: (1) the
most widely used antibiotic regimen was the combination of
beta-lactam plus macrolide, though there was considerable
heterogeneity in antibiotic regimens. (2) Rates of adherence
to guidelines of the SEPAR were high, but differed among the
hospitals. (3) Patients treated with other regimens had an
increased mortality risk (OR ¼ 3, 1.2–7.3). (4) Beta-lactam
monotherapy was independently associated with re-admis-
sion. (5) LOS was not independently inﬂuenced by empiric
treatment and it was related to the admitting hospital.
The characteristics of study population were similar in all
four hospitals, and similar to those of other studies of CAP in
hospitalized subjects. The choice of empirical treatment
was based on the guidelines of the SEPAR6,7 in a large
percentage of patients (76.5%), though with differences in
adherence among the four hospitals.
The global results show the most common treatment
regimen to be the combination of a beta-lactam plus
macrolide, similar to the ﬁndings of other studies.5,13
Nevertheless, it should be pointed out that in 9–31% of
cases, antibiotic regimens different from those recommended
by the Spanish guidelines were used. Thus, in hospital B,
more alternative antibiotic regimens were prescribed, due to
an increased use of second-generation cephalosporins plus
ARTICLE IN PRESS
S. Reyes Calzada et al.1914a macrolide. Although this practice does not adhere to
Spanish guidelines, it does comply with the previous Amer-
ican guidelines.23 Besides inertia to previous practice, Cabana
et al.24 analysed the reasons for non-adherence to guidelines.
They found out many potential barriers to physician guideline
adherence, including lack of awareness, familiarity, agree-
ment, self-efﬁcacy and outcome expectancy. In a recent
publication, it has been found that other non-pneumologist
specialists had a lower adherence to guidelines compared to
pneumologists and residents.25 Unfortunately, in the current
study we have not speciﬁcally investigated these reasons.
The distribution of the antibiotic regimens according to
PSI was similar in both the low and high-risk groups, with the
exception of an increased use of macrolide monotherapy in
lowest risk classes.
The mortality rate in our study (8.2%) was similar to that
reported by other authors,26–29 and was adjusted to the PSI.
Noteworthy, mortality was greater (though not statistically
signiﬁcant) in patients administered other regimens. Other
authors have previously reported lower mortality when
treatment adheres to the guidelines.4,13,30
A detailed analysis of the antibiotic regimens employed in
our study shows global mortality to be greater among the
patients administered other regimens (13.6% versus 8.2%).
On analysing the high-risk patients, mortality among those
receiving other regimens was seen to increase signiﬁcantly
(24.3% versus 6.8% and 13.1%). In fact, the difference for
each antibiotic regimen between actual and PSI-predicted
mortality (Fig. 1) clearly reﬂects the increased mortality in
those treated with other non-adherent regimens. The
opposite was observed for the rest of antibiotic regimens,
where actual mortality was lower than predicted by
PSI. Likewise, other authors4,10,14 also reported increased
mortality in the group of patients administered other
regimens. In the multivariate analysis to predict mortality
following adjustment for PSI, other regimens were indepen-
dently associated to increased mortality (OR ¼ 3, 1.2–7.3).
In the low risk patients, mortality among those treated
with macrolides and quinolones as monotherapy was lower
than in those administered beta-lactam monotherapy,
though statistical signiﬁcance was not reached. However,
these ﬁndings should be interpreted with caution, due to the
few patients treated with this regimen, and in view of the
low mortality inherent to low PSI.
The LOS showed no signiﬁcant differences for the
different antibiotic regimens. In fact, the hospital where
the patient was admitted exerted greater inﬂuence. The
LOS was shorter in hospital D (OR ¼ 0.2, 0.1–0.5), and was
unrelated to adherence or non-adherence to the guidelines
or to the use of macrolides. Several investigators12,15,31,32
found shorter LOS in patients treated with macrolides,
though not all authors corroborate this ﬁnding.18 Probably,
the LOS is more dependent upon factors inherent to the
patient and to the hospital involved.33–35 Despite differ-
ences in LOS among hospitals, we did not ﬁnd differences on
mortality.35 A clinical pathway was successful in reducing
consumption of resources and LOS without causing adverse
effect on mortality and re-admissions.36
The rate of overall re-admission was 7.6%, and tended to
be greater among patients given beta-lactam monotherapy,
especially in severe CAP (classes IV and V). The multivariate
study showed beta-lactam monotherapy to be an indepen-dent risk factor for re-admission. Hardly any data are found
in the literature on re-admission in CAP and the different
antibiotic regimens used.37
Among the limitations of the present study, mention
should be made of the few patients treated with quinolones,
coincident with the withdrawal of some of these drugs (e.g.,
trovaﬂoxacin) from the market. Therefore, the results of
this group of antibiotics should not be extrapolated to the
current situation. Since our study was not randomized, the
degree of evidence is not the best, though it would not have
been ethical to apply such a design in which a group of
patients would be administered antibiotic regimens not
recommended by the guidelines.
In conclusion, important adherence to the hospitalized
CAP treatment guidelines is observed, though with con-
siderable variability in the empirical antibiotic treatments
used in daily clinical practice. Regimens not adhering to the
guidelines are associated with greater mortality in CAP and
not related to LOS. The beta-lactams are associated with
increased re-admission, though further studies are needed
to conﬁrm this ﬁnding. LOS was related to the hospital more
than to the antimicrobial treatment.
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